A.R.T. Advisors’s NovoCure NVCR Stock Holding History

A.R.T. Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,470	Closed	-$882K	–	675
2019 Q4	$882K	Buy	+10,470	New	+$845K	0.04%	614
2019 Q3	–	Sell	-10,370	Closed	-$656K	–	1635
2019 Q2	$656K	Sell	10,370 -16,800	-62%	-$851K	0.04%	628
2019 Q1	$1.31M	Buy	+27,170	New	+$1.31M	0.08%	381
2018 Q2	–	Sell	-36,905	Closed	-$804K	–	1667
2018 Q1	$804K	Sell	36,905 -41,500	-53%	-$893K	0.03%	743
2017 Q4	$1.58M	Sell	78,405 -18,000	-19%	-$347K	0.07%	454
2017 Q3	$1.91M	Buy	96,405 +31,900	+49%	+$627K	0.1%	294
2017 Q2	$1.11M	Buy	64,505 +38,779	+151%	+$501K	0.06%	474
2017 Q1	$208K	Buy	+25,726	New	+$186K	0.01%	1153
2016 Q3	–	Sell	-59,500	Closed	-$694K	–	1003
2016 Q2	$694K	Buy	+59,500	New	+$745K	0.03%	682

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

A.R.T. Advisors's NVCR Position: Q1 2020 in Review

A.R.T. Advisors sold out of NovoCure (NVCR) in Q1 2020, closing a stake of 10,470 shares — an estimated $882K sold.

A.R.T. Advisors first reported a position in NVCR in Q2 2016 and held it in 9 quarters. The position peaked at $1.91M in Q3 2017. 271 funds tracked by Wall St. Rank hold NVCR as of Q1 2020.

A.R.T. Advisors reported no remaining NovoCure position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 10,470 NovoCure shares in Q1 2020, an estimated $882K.
A.R.T. Advisors first reported a position in NovoCure in Q2 2016 and held it in 9 quarters.
A.R.T. Advisors's NovoCure position peaked at $1.91M in Q3 2017.
271 funds tracked by Wall St. Rank held NovoCure as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.